var data={"title":"Cyclophosphamide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cyclophosphamide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5959?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">see &quot;Cyclophosphamide: Drug information&quot;</a> and <a href=\"topic.htm?path=cyclophosphamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cyclophosphamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155456\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Procytox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046686\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25472595\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> For oncology uses, details concerning dosing in combination regimens should also be consulted; antiemetics may be recommended (emetogenic potential varies by dose and combination therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuroblastoma:</b> Limited data available: <i>INES 99.1 regimen courses 1 and 2:</i> Term neonates: IV: 3.5 mg/kg on Days 1 to 5 administered at 2-week intervals for 2 cycles initially, in combination with vincristine (Rubie 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046677\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">see &quot;Cyclophosphamide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">For oncology uses, all dosing presented based on clinically recognized trials; consult specific regimens concerning dosing in combination regimens. Doses IV &ge;1,000 mg/m<sup>2</sup> are associated with a high emetic potential and IV doses &lt;1,000 mg/m<sup>2</sup> and all oral doses are associated with a moderate emetic risk (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Dupuis 2013; Roila 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> In pediatric patients, dosing may be based on either BSA (mg/<b>m<sup>2</sup></b>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations. To lessen potential toxicity with doses for oncologic uses, hydration, and follow-up mesna therapy are typically administered; refer to specific protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oncologic uses:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Acute lymphoblastic leukemia, high-risk:</b> Limited data available (Steinherz 1993): NYII Protocol:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: Children and Adolescents: IV: 1,200 mg/<b>m<sup>2</sup></b> on Day 2 (in combination with steroid, daunorubicin, vincristine, and asparaginase)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance I: Children and Adolescents: IV: 600 mg/<b>m<sup>2</sup></b>on Day 4 (in combination with steroid, mercaptopurine, vincristine, daunorubicin, methotrexate, cytarabine, and thioguanine)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Acute lymphoblastic leukemia, relapsed or refractory:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Hijiya 2011</i>: Children and Adolescents: IV: 440 mg/<b>m<sup>2</sup></b> over 30 to 60 minutes in combination with clofarabine and etoposide; number of doses dependent on phase of protocol: Induction: Days 1 to 5, and Consolidation: Days 1 to 4</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Parker 2010</i>: UK-ALL R3 protocol: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Phase 2 Consolidation (weeks 5 to 8): IV: 440 mg/<b>m<sup>2</sup></b> on Days 15 to 19 in combination with steroid, vincristine, methotrexate, PEG-asparaginase, and etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Phase 5, before Continuation (weeks 14 to 29): IV: 300 mg/<b>m<sup>2</sup></b> on Days 42, 49, 99, and 106 in combination with steroid, mercaptopurine, vincristine, methotrexate, etoposide, and cytarabine</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>CNS tumors, malignant (medulloblastoma, PNET, ependymoma, brainstem glioma):</b> Limited data available (Chi 2004; Mason 1998): Head Start II Protocol: Infants and Children &lt;10 years: IV: 65 mg/kg on Days 2 and 3 with mesna every 21 days for 5 cycles (in combination with cisplatin, vincristine, etoposide, and high-dose methotrexate; then followed by an auto-transplantation)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Desmoplastic small round cell tumor (DSRCT):</b> Limited data available (Kushner 1996): High-dose cyclophosphamide: HD-CAV/IE regimen: P6 Protocol:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;10 years: IV: 70 mg/kg over 6 hours with mesna and hydration on Days 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children <i>&ge;</i>10 years and Adolescents: IV: 2,100 mg/<b>m<sup>2</sup></b>over 6 hours with mesna and hydration on Day 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Ewing sarcoma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>VAC/IE regimen:</i> Limited data available (Grier 2003): Children and Adolescents: IV: 1,200 mg/<b>m<sup>2</sup></b> with mesna on Day 1 of a 21-day treatment cycle in combination with vincristine and doxorubicin (then dactinomycin when maximum doxorubicin dose reached), alternate with IE (ifosfamide and etoposide) for a total of 17 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>High-dose cyclophosphamide: HD-</i>\n      <i>CAV/IE</i> <i>regimen:</i> P6 Protocol: Limited data available (Kushner 1996):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &lt;10 years: IV: 70 mg/kg over 6 hours with mesna and hydration on Days 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;10 years and Adolescents: IV: 2,100 mg/<b>m<sup>2</sup></b> over 6 hours with mesna and hydration on Days 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Hogkin lymphoma: </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>BEACOPP (high-risk):</i> Children and Adolescents: IV: 1,200 mg/<b>m<sup>2</sup></b> on Day 0 of a 21-day treatment cycle for 4 cycles in combination with bleomycin, etoposide, doxorubicin, vincristine, prednisone, and procarbazine (Kelly 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>ABVE-PC </i>\n      <i>(intermediate-risk</i>): Children and Adolescents: IV: 800 mg/<b>m<sup>2</sup></b> over 1 hour on the first day of a 21-day cycle for up to 4 cycles (depending upon response) in combination with doxorubicin, vincristine, etoposide, prednisone, and bleomycin (Dharmarajan 2015; Friedman 2014; Schwartz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>HSCT conditioning; myeloablative transplant: </b> Limited data available: Infants, Children, and Adolescents: IV: 50 mg/kg/day for 4 days beginning 5 days before transplant (Champlin 2007); other regimens have used 60 mg/kg/day for 2 days following busulfan (Locatelli 2005; M&aring;rtensson 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosing adjustment in obese patients:</i> American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity (Bubalo 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Cy200 (cyclophosphamide total dose of 200 mg/kg): Use the lesser of ideal body weight (IBW) or actual body weight (ABW)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Cy120 (cyclophosphamide total dose of 120 mg/kg): Use ABW25 for patients &gt;120% IBW</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">ABW25: Adjusted weight (kg) = Ideal body weight (kg) + 0.25 [actual wt (kg) - ideal body weight (kg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Neuroblastoma during infancy (unresectable): </b>Limited data available (Rubie 2011): INES 99.1 regimen courses 1 and 2:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;10 kg: IV: 3.5 mg/kg on Days 1 to 5 administered at 2-week intervals for 2 cycles initially, in combination with vincristine</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;10 kg: IV: 5 mg/kg on Days 1 to 5 administered at 2-week intervals for 2 cycles initially, in combination with vincristine</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Neuroblastoma</b>\n      <b>; high-risk, newly diagnosed:</b> Limited data available (Park 2011): Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction cycles 1 and 2 (21-day cycles):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &le;12 kg: IV: 13.3 mg/kg over 30 minutes on Days 1 to 5 (in combination with topotecan) for 2 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &gt;12 kg: IV: 400 mg/<b>m<sup>2</sup></b>over 30 minutes on Days 1 to 5 (in combination with topotecan) for 2 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction cycles 4 and 6 (21-day cycles):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &le;12 kg: IV: 70 mg/kg over 6 hours with mesna on Days 1 and 2 (in combination with doxorubicin and vincristine)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &gt;12 kg: IV: 2,100 mg/<b>m<sup>2</sup></b> over 6 hours with mesna on Days 1 and 2 (in combination with doxorubicin and vincristine)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Neuroblastoma; relapsed or refractory:</b> Limited data available (Kushner 2010; Kushner 2011): HD-CCV or HD-CTV regimen: Infants and Children &le;10 years: IV: 70 mg/kg on Days 1 and 2 (in combination with irinotecan and vincristine or in combination with topotecan and vincristine)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Non-Hodgkin lymphoma: </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">COP regimen: Reduction: Infants &ge;6 months, Children, and Adolescents: IV: 300 mg/<b>m<sup>2</sup></b>over 15 minutes on Day 1 (in combination with vincristine and prednisone) (Cairo 2007; Goldman 2013; Goldman 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">COPADM 1 regimen: Induction 1: Infants &ge;6 months, Children, and Adolescents: IV: 250 mg/<b>m<sup>2</sup></b>/dose over 15 minutes every 12 hours on Days 2 to 4 (6 doses) (in combination with doxorubicin, vincristine, prednisone, methotrexate) (Cairo 2007; Goldman 2013; Goldman 2014; Patte 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">COPADM 2 regimen: Induction 2: Infants &ge;6 months, Children, and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b>/dose over 15 minutes every 12 hours on Days 2 to 4 (6 doses) (in combination with doxorubicin, vincristine, prednisone, methotrexate, +/- Rituximab) (Cairo 2007; Goldman 2013; Goldman 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">COPADM regimen: Maintenance 1: High-risk patients: Infants &ge;6 months, Children, and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b> over 15 minutes on Days 2 and 3 (2 doses) (in combination with doxorubicin, vincristine, prednisone, methotrexate) (Cairo 2007; Goldman 2013; Goldman 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">COPA regimen: Maintenance course 3: High-risk patients: Infants &ge;6 months, Children, and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b>/dose over 30 minutes on the first 2 days of the cycle (2 doses) (in combination with doxorubicin, vincristine, prednisone) (Cairo 2007; Goldman 2013; Goldman 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Non-Hodgkin lymphoma, T-cell (anaplastic large cell lymphoma [ALCL])</b>: Limited data available (Reiter 1994; Seideman 2001): NHL-BFM90 protocol: Infants, Children, and Adolescents: IV: 200 mg/<b>m<sup>2</sup></b>over 1 hour; number of doses, days of administration, and other chemotherapy combinations are dependent on protocol specific phase</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Palliative intent chemotherapy (metronomic therapy):</b> Limited data available: Infants, Children, and Adolescents: Oral: 2.5 mg/kg once daily, maximum dose: 100 mg/dose for 21 days, alternating with a 21-day cycle of etoposide in combination with continuous thalidomide, celecoxib, and fenofibrate therapy; in the trial, the youngest patient reported was 191 days old (around 6 months of age) (Robison 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Post-transplant lymphoproliferative disease (PTLD):</b> Limited data available: Infants, Children, and Adolescents: IV: 600 mg/<b>m<sup>2</sup></b> on Day 1 every 21 days for 6 cycles in combination with prednisone (all 6 cycles) and rituximab (first 2 cycles only); the youngest patient included in the reported experience was 0.8 years of age (Gross 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Retinoblastoma, extraocular:</b> Limited data available (Chantada 2003): Protocol 94 regimen: Children: IV: 65 mg/kg over 1 hour on Day 1 with mesna of a 21-day treatment cycle (in combination with idarubicin and vincristine) alternating cycles with carboplatin and etoposide for a total of 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Rhabdomyosarcoma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Low risk: </i>Limited data available (Walterhouse 2014): VAC regimen: Doses were administered with hydration and mesna every 21 days for 4 doses of a 22-week cycle in combination with vincristine and dactinomycin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &lt;3 years: IV: 40 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;3 years and Adolescents: 1,200 mg/<b>m<sup>2</sup></b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Intermediate risk</i>: Limited data available (Arndt 2009): VAC regimen: Doses were administered with hydration and mesna every 21 days for 14 cycles in combination with vincristine and dactinomycin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: IV: 36 mg/kg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 1 to 3 years: IV: 73 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children <i>&gt;</i>3 years: 2,200 mg/<b>m<sup>2</sup></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Wilms tumor; anaplastic (stage II to IV): </b>Limited data available (Green 1994): National Wilms&rsquo; Tumor Study (NWTS) protocol 4 regimen J: Children and Adolescents &lt;16 years: IV: 10 mg/kg on Days 1 to 3 (3 doses) every 6 weeks (in combination with vincristine, dactinomycin, and doxorubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Wilms tumor relapsed or refractory: </b>Limited data available: National Wilms&rsquo; Tumor Study (NWTS) protocol-5 regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children weighing &le;30 kg: IV: 14.7 mg/kg with mesna; reported frequency and combination chemotherapy variable, refer to specific protocols. One regimen alternated the frequency based on week of therapy: Weeks 3, 9, 15, and 21: Doses administered once daily for 5 days (in combination with etoposide); Weeks 6, 12, 18, and 24 administered once daily for 3 days (in combination with doxorubicin and vincristine) (Green 2007); another protocol administered for 5 days, on Weeks 0 and 3 in combination with etoposide; alternate with carboplatin and etoposide on Weeks 6 and 9 and continued for 90 weeks (Malogolowkin 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;30 kg and Adolescents &lt;16 years at diagnosis: IV: 440 mg/<b>m<sup>2 </sup></b>with mesna; reported frequency and combination chemotherapy variable, refer to specific protocols. One regimen alternated the frequency based on week of therapy: Weeks 3, 9, 15, and 21: Doses administered once daily for 5 days (in combination with etoposide); Weeks 6, 12, 18, and 24 administered once daily for 3 days (in combination with doxorubicin and vincristine) (Green 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-Oncologic uses:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Aplastic anemia, severe; refractory:</b> Limited data available: Children and Adolescents &ge;2 years: High-dose therapy: IV: 45 to 50 mg/kg/day for 4 days has been used in several small trials; concurrent prophylactic antimicrobial therapy should be considered (Audino 2010; Brodsky 1996; Brodsky 2010; DeZern 2011; Jaime-Perez 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Kawasaki Disease; refractory to multiple therapies:</b> Very limited data available: Infants and Young Children: IV: 2 mg/kg/dose once daily; some have suggested a gradual taper over 1.5 to 7 months; however, details of taper have not been described. Dosing based on a retrospective study of patients with refractory Kawasaki Disease that included two patients (ages 2.7 and 9 years) who had failed to respond to 3 doses of IVIG and required high-dose IV methylprednisolone; after initiation of cyclophosphamide, steroids were able to be successfully tapered and final ECHO showed resolution of aneurysm. While taper schedule was not described, both patients were discharged on a taper over 1.5 to 7 months (AHA [McCrindle 2017]; Wallace 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Lupus nephritis; proliferative:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial phase; pulse therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">6-month course: Usual range: 500 to 1,000 mg/<b>m<sup>2</sup></b>/dose once monthly (KDIGO 2012); the following regimen has been used for dosage escalation: Initial: 500 mg/<b>m<sup>2</sup></b> then titrate as tolerated every 4 weeks in 250 mg/<b>m<sup>2</sup></b> increments up to 750 or 1,000 mg/<b>m<sup>2</sup></b> every month; maximum monthly dose: 1,500 mg/month (Bertsias 2012; Mina 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3-month course: 500 mg every 2 weeks for 3 months (Bertsias 2012; KDIGO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 1 to 1.5 mg/kg/day for 2 to 4 months; maximum daily dose: 150 mg/<b>day</b> (KDIGO 2012); higher doses (2 to 2.5 mg/kg/day for 3 months) may be required in patients with worsening prognostic factors (eg, acute renal function deterioration) (Bertsias 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance phase: IV: 500 to 1,000 mg/<b>m<sup>2</sup></b> every 3 months for a total of 1.5 to 3 years has been used; however, current guidelines recommend other oral immunosuppressive agents for maintenance therapy (KDIGO 2012; Kliegman 2011; Lehman 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Nephrotic syndrome, minimal change (frequently relapsing):</b> Infants, Children, and Adolescents: Oral: 2 mg/kg/day for 8 to 12 weeks; reported range: 2 to 3 mg/kg/day; maximum cumulative dose: 168 mg/kg; dosing based on ideal bodyweight (Gipson 2009; KDIGO 2012; KDOQI 2013). Treatment beyond 90 days may increase the potential for sterility in males.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Uveitis, severe; recalcitrant, high-risk vision loss:</b> Limited data available: Children and Adolescents: Oral: Initial: 2 mg/kg/day once daily; usual reported range: 1 to 3 mg/kg/day in combination with corticosteroids (which may be decreased while on cyclophosphamide) (Jabs 2000; Pujari 2010; Simonini 2010); dosing based on large, multicenter report of 215 patients with ocular inflammatory disease which included 44 patients with uveitis (age range: 11.5 to 76.4 years); after 12 months of therapy ~89% of patients had no inflammatory disease activity or only slightly active disease (Pujari 2010). <b>Note:</b> Some data suggests that pulse intravenous therapy may be less effective than oral cyclophosphamide (Pujari 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Vasculitis, ANCA-associated (eg, granulomatosis with polyangiitis [GPA], Wegener granulomatosis):</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Initial: 15 mg/kg every 2 weeks for 3 doses, then 15 mg/kg every 3 weeks until remission or azathioprine maintenance; dosing based on experience from a pediatric case series (n=5) and a larger adult trial (n=76); in the pediatric case series, the median cumulative dose was 90 mg/kg (range: 63 to 115 mg/kg), most patients received 6 to 7 pulses of therapy; in the adult trial, therapy was continued for 3 months after remission (de Groot 2009; Krmar 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 2 mg/kg/day in combination with corticosteroids until remission; a subsequent decrease in dose to 1.5 mg/kg/day for another 3 months has been reported (de Groot 2009; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Malignancy:</b> For non-HSCT dosing: Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 40 to 50 mg/kg in divided doses over 2 to 5 days <b>or</b> 10 to 15 mg/kg every 7 to 10 days <b>or</b> 3 to 5 mg/kg twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 1 to 5 mg/kg/day (initial and maintenance dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; decreased renal excretion of cyclophosphamide and its metabolites may occur; monitor patients with severe impairment (CrCl 10 to 24 mL/min) for signs and symptoms of toxicity. The following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Aronoff 2007:</i> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;10 mL/minute: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Moderately dialyzable (20% to 50%); administer 50% of normal dose; administer after hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 100% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>KDIGO 2012:</i> <b>Lupus nephritis:</b> Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 25 to 50 mL/minute: Administer 80% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to &lt;25 mL/minute: Administer 70% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Aronoff 2007: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;10 mL/minute: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Moderately dialyzable (20% to 50%); administer 50% of normal dose; administer after hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 100% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Janus 2010:</i> Hemodialysis: Administer 75% of normal dose; administer after hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hematopoietic stem cell transplantation (Bodge 2014):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe impairment: Consider dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer after hemodialysis. Cyclophosphamide is 20% to 50% dialyzed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>International Myeloma Working Group (IMWG) Recommendations:</i> The International Myeloma Working Group (IMWG) recommendations suggest that cyclophosphamide may be administered without dosage adjustment in multiple myeloma patients with renal impairment, including those on dialysis. The IMWG recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine (Dimopoulos 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; in severe hepatic impairment, conversion to an active metabolite may be reduced potentially affecting efficacy. The half-life and clearance of cyclophosphamide metabolites may be increased/decreased respectively.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following adjustments have been recommended (Floyd 2006): All patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum bilirubin 3.1 to 5 mg/dL or transaminases &gt;3 times ULN: Administer 75% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum bilirubin &gt;5 mg/mL: Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155426\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg [DSC], 50 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155411\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046690\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Cyclophosphamide is associated with a moderate to high emetic potential (depending on dose or regimen); antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Dupuis 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Capsules and tablets should be swallowed whole. Tablets are not scored and should not be cut, crushed, or chewed. Capsules should not be opened, crushed, or chewed. Wear gloves when handling capsules/tablets and container; avoid exposure to broken capsules. If exposure to capsule contents or crushed/cut tablets, wash hands immediately and thoroughly. Morning administration may be preferred to ensure adequate hydration throughout the day; do not administer tablets/capsules at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: May administer reconstituted solution without further dilution (20 mg/mL); rate may vary based on protocols (refer to specific protocols)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion (intermittent or continuous): Infusion rate may vary based on protocol (refer to specific protocol for infusion rate); usually over 15 to 60 minutes; larger doses (&gt;1,800 mg/m<sup>2</sup>) have been infused over 1 to 6 hours by some centers and protocols</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bladder toxicity: To minimize bladder toxicity, increase normal fluid intake during and for 1 to 2 days after cyclophosphamide dose. Most adult patients will require a fluid intake of at least 2 L/day and in pediatric patients twice maintenance (3 L/m<sup>2</sup>/day). High-dose regimens and depending upon the protocol some standard (low) cyclophosphamide doses should be accompanied by vigorous hydration with mesna therapy (refer to specific protocols and Mesna monograph for additional information). Morning administration may be preferred to ensure adequate hydration throughout the day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematopoietic stem cell transplant: Adults: Approaches to reduction of hemorrhagic cystitis include infusion of NS 3 L/m<sup>2</sup>/24 hours, infusion of NS 3 L/m<sup>2</sup>/24 hours with continuous NS bladder irrigation 300 to 1,000 mL/hour, and infusion of NS 1.5 to 3 L/m<sup>2</sup>/24 hours with intravenous mesna. Hydration should begin at least 4 hours before cyclophosphamide and continue at least 24 hours after completion of cyclophosphamide. The dose of daily mesna (as a percentage of cyclophosphamide dose) may vary; refer to protocol and/or primary literature for mesna dose. Mesna can be administered as a continuous 24-hour intravenous infusion or be given in divided doses every 4 hours. Mesna should begin at the start of treatment and continue at least 24 hours following the last dose of cyclophosphamide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130947\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs). Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155448\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection powder for reconstitution: Store intact vials of powder at &le;25&deg;C (77&deg;F). Exposure to excessive temperatures during transport or storage may cause active ingredient to melt (vials with melting may have a clear to yellow viscous liquid which may appear as droplets); do not use vials with signs of melting. Solutions reconstituted in sterile water for injection should be further diluted immediately. According to the manufacturer, reconstituted solutions in normal saline (NS) are stable for 24 hours at room temperature and for 6 days refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Solutions diluted for infusion in <sup>1</sup>/<sub>2</sub>NS are stable for 24 hours at room temperature and for 6 days refrigerated and solutions diluted in D5W or D5NS are stable for 24 hours at room temperature and for 36 hours refrigerated (according to product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store tablets at &le;25&deg;C (77&deg;F); brief excursions are permitted up to 30&deg;C (86&deg;F); protect from temperatures &gt;30&deg;C (86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046689\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oncologic uses:</b> Treatment of Hodgkin lymphoma, non-Hodgkin lymphomas (including Burkitt lymphoma), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute lymphocytic leukemia (ALL), mycosis fungoides, multiple myeloma, neuroblastoma, retinoblastoma, breast cancer, ovarian adenocarcinoma [Oral, parenteral: All indications: FDA approved in pediatric patients (age not specified) and adults]; has also been used for Ewing sarcoma, rhabdomyosarcoma, Wilms tumor, ovarian germ cell tumors, small cell lung cancer, testicular cancer, pheochromocytoma, CNS tumors, and in hematopoietic stem cell transplant (HSCT) conditioning regimens</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nononcologic uses:</b> Treatment of minimal change nephrotic syndrome [Oral: FDA approved in pediatric patients (age not specified)]; has also been used for treatment of aplastic anemia, lupus nephritis, uveitis, vasculitis (ANCA positive, eg, granulomatosis with polyangiitis [GPA]; Wegener granulomatosis) and Kawasaki Disease refractory to IVIG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155519\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cyclophosphamide may be confused with cycloSPORINE, ifosfamide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cytoxan may be confused with cefOXitin, Ciloxan, cytarabine, CytoGam, Cytosar, Cytosar-U, Cytotec</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Cyclophosphamide is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155515\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (reversible; onset: 3 to 6 weeks after start of treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Altered hormone level (increased gonadotropin secretion), amenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, mucositis, nausea and vomiting (dose-related), stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azoospermia, defective oogenesis, hemorrhagic cystitis, oligospermia, sterility</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression, febrile neutropenia, leukopenia (dose-related; recovery: 7 to 10 days after cessation), neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute respiratory distress, anaphylaxis, auditory disturbance, blurred vision, cardiac arrhythmia (with high-dose [HSCT] therapy), cardiac failure (with high-dose [HSCT] therapy), cardiac tamponade (with high-dose [HSCT] therapy), cardiotoxicity, confusion, C-reactive protein increased, dizziness, dyschromia (skin/fingernails), dyspnea, erythema multiforme, gastrointestinal hemorrhage, heart block, hematuria, hemopericardium, hemorrhagic colitis, hemorrhagic myocarditis (with high-dose [HSCT] therapy), hemorrhagic ureteritis, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatitis, hepatotoxicity, hypersensitivity reaction, hyperuricemia, hypokalemia, hyponatremia, increased lactate dehydrogenase, interstitial pneumonitis, jaundice, malaise, mesenteric ischemia (acute), metastases, methemoglobinemia (with high-dose [HSCT] therapy), multi-organ failure, myocardial necrosis (with high-dose [HSCT] therapy), neurotoxicity, neutrophilic eccrine hidradenitis, ovarian fibrosis, pancreatitis, pericarditis, pneumonia, pulmonary hypertension, pulmonary infiltrates, pulmonary interstitial fibrosis (with high doses), pulmonary veno-occlusive disease, pyelonephritis, radiation recall phenomenon, reactivation of disease, reduced ejection fraction, renal tubular necrosis, reversible posterior leukoencephalopathy syndrome, rhabdomyolysis, sepsis, septic shock, SIADH, skin rash, Stevens-Johnson syndrome, testicular atrophy, thrombocytopenia (immune-mediated), thrombosis (arterial and venous), toxic epidermal necrolysis, toxic megacolon, tumor lysis syndrome, urinary fibrosis, weakness, wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155434\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity to cyclophosphamide or any component of the formulation; urinary outflow obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to cyclophosphamide or its metabolites, urinary outflow obstructions, severe myelosuppression, severe renal or hepatic impairment, active infection (especially varicella zoster), severe immunosuppression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155415\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Leukopenia, neutropenia, thrombocytopenia, and anemia may commonly occur; may be dose related. Bone marrow failure has been reported. Bone marrow failure and severe immunosuppression may lead to serious (and fatal) infections, including sepsis and septic shock, or may reactive latent infections. Antimicrobial prophylaxis may be considered in appropriate patients. Initiate antibiotics for neutropenic fever; antifungal and antiviral medications may also be necessary. Monitor blood counts during treatment. Avoid use if neutrophils are &le;1,500/mm<sup>3</sup> and platelets are &lt;50,000/mm<sup>3</sup>. Consider growth factors (primary or secondary prophylaxis) in patients at increased risk for complications due to neutropenia. Platelet and neutrophil nadirs are usually at weeks 1 and 2 of treatment and recovery is expected after ~20 days. Severe myelosuppression may be more prevalent in heavily pretreated patients or in patients receiving concomitant chemotherapy and/or radiation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiotoxicity: Cardiotoxicity has been reported (some fatal), usually with high doses associated with transplant conditioning regimens, although may rarely occur with lower doses. Cardiac abnormalities do not appear to persist. Cardiotoxicities reported have included arrhythmias (supraventricular and ventricular [some with QT prolongation]), congestive heart failure, heart block, hemopericardium (secondary to hemorrhagic myocarditis and myocardial necrosis), myocarditis (including hemorrhagic), pericarditis, pericardial effusion including cardiac tamponade, and tachyarrhythmias. Cardiotoxicity is related to endothelial capillary damage; symptoms may be managed with diuretics, ACE inhibitors, beta-blockers, or inotropics (Floyd 2005). The risk for cardiotoxicity may be increased with higher doses, advanced age, prior radiation to the cardiac region, and in patients who have received prior or concurrent cardiotoxic medication. Use with caution in patients with preexisting cardiovascular disease or those at risk for cardiotoxicity. For patients with cardiac risk factors or preexisting cardiac disease, monitor during treatment. In a scientific statement from the American Heart Association, cyclophosphamide has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fertility effects: May impair fertility; interferes with oogenesis and spermatogenesis. Effect on fertility is generally dependent on dose and duration of treatment and may be irreversible. The age at treatment initiation and cumulative dose were determined to be risk factors for ovarian failure in cyclophosphamide use for the treatment of systemic lupus erythematosus (SLE) (Mok 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal adverse effects: Nausea and vomiting commonly occur. Cyclophosphamide is associated with a moderate to high emetic potential (depending on dose, regimen, or administration route); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016). Stomatitis/mucositis may also occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatic sinusoidal obstruction syndrome (SOS), formerly called veno-occlusive liver disease (VOD), has been reported in patients receiving chemotherapy regimens containing cyclophosphamide. A major risk factor for SOS is cytoreductive conditioning transplantation regimens with cyclophosphamide used in combination with total body irradiation or busulfan (or other agents). Other risk factors include preexisting hepatic dysfunction, prior radiation to the abdominal area, and low performance status. Children &lt;3 years of age are reported to be at increased risk for hepatic SOS; monitor for signs or symptoms of hepatic SOS, including bilirubin &gt;1.4 mg/dL, unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt 2004). SOS has also been reported in patients receiving long-term lower doses for immunosuppressive indications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylactic reactions have been reported. Cross-sensitivity with other alkylating agents may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyponatremia: Hyponatremia associated with increased total body water, acute water intoxication, and a syndrome resembling SIADH (syndrome of inappropriate secretion of antidiuretic hormone) has been reported; some have been fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Monitor for infections; immunosuppression and serious infections may occur. Serious infections may require dose reduction, or interruption or discontinuation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicities: Pulmonary toxicities, including pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease, and acute respiratory distress syndrome, have been reported. Monitor for signs/symptoms of pulmonary toxicity. Consider pulmonary function testing to assess the severity of pneumonitis (Morgan 2011). Cyclophosphamide-induced pneumonitis is rare and may present as early (within 1 to 6 months) or late onset (several months to years). Early onset may be reversible with discontinuation; late onset is associated with pleural thickening and may persist chronically (Malik 1996). In addition, late onset pneumonitis (&gt;6 months after therapy initiation) may be associated with increased mortality.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Secondary malignancies (bladder cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported with both single-agent and with combination chemotherapy regimens; onset may be delayed (up to several years after treatment). Bladder cancer usually occurs in patients previously experiencing hemorrhagic cystitis; risk may be reduced by preventing hemorrhagic cystitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary/renal toxicity: Cyclophosphamide is associated with the development of hemorrhagic cystitis, pyelitis, ureteritis, and hematuria. Hemorrhagic cystitis may rarely be severe or fatal. Bladder fibrosis may also occur, either with or without cystitis. Urotoxicity is due to excretion of cyclophosphamide metabolites in the urine and appears to be dose- and treatment duration-dependent, although may occur with short-term use. Increased hydration and frequent voiding is recommended to help prevent cystitis; some protocols utilize mesna to protect against hemorrhagic cystitis. Monitor urinalysis for hematuria or other signs of urotoxicity. Severe or prolonged hemorrhagic cystitis may require medical or surgical treatment. While hematuria generally resolves within a few days after treatment is withheld, it may persist in some cases. Discontinue cyclophosphamide with severe hemorrhagic cystitis. Exclude or correct any urinary tract obstructions prior to treatment initiation (use is contraindicated with bladder outlet obstruction). Use with caution (if at all) in patients with active urinary tract infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing impairment: May interfere with wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be needed. The conversion between cyclophosphamide to the active metabolite may be reduced in patients with severe hepatic impairment, potentially reducing efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be needed. Decreased renal excretion and increased serum levels (cyclophosphamide and metabolites) may occur in patients with severe renal impairment (CrCl 10 to 24 mL/minute); monitor for signs/symptoms of toxicity. Cyclophosphamide and metabolites are dialyzable; differences in amount dialyzed may occur due to dialysis system used. If dialysis is required, maintain a consistent interval between administration and dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Cyclophosphamide may potentiate the cardiotoxicity of anthracyclines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155504\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155420\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13191&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, bone marrow suppression.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Cyclophosphamide may enhance the adverse/toxic effect of Amiodarone. Specifically, the risk of pulmonary toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anthracyclines: Cyclophosphamide may enhance the cardiotoxic effect of Anthracyclines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the hepatotoxic effect of Cyclophosphamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May enhance the adverse/toxic effect of Cyclophosphamide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Cyclophosphamide may enhance the immunosuppressive effect of CycloSPORINE (Systemic). Cyclophosphamide may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Inducers (Moderate): May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etanercept: May enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Filgrastim: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be enhanced. Cyclophosphamide may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of bleomycin infusion. Monitor for enhanced pulmonary toxicity when cyclophosphamide and lenograstim are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be increased. Cyclophosphamide may diminish the therapeutic effect of Lipegfilgrastim. Management: Lipegfilgrastim should be administered at least 24 hours after the completion of cyclophosphamide. Consider monitoring for enhanced pulmonary toxicity when cyclophosphamide and lipegfilgrastim are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mivacurium: Cyclophosphamide may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentostatin: May enhance the cardiotoxic effect of Cyclophosphamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the incidences of neutropenia, infection, and mucositis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: Cyclophosphamide may enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Cyclophosphamide may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days, or reduced succinylcholine doses (a serum pseudocholinesterase assay may help inform this reduction) with close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, granulocytopenia may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155422\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13494887\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Cyclophosphamide crosses the placenta and can be detected in amniotic fluid (D'Incalci 1982). Based on the mechanism of action, cyclophosphamide may cause fetal harm if administered during pregnancy. Adverse events (including ectrodactylia) were observed in human studies following exposure to cyclophosphamide. Women of childbearing potential should avoid pregnancy while receiving cyclophosphamide and for up to 1 year after completion of  treatment. Males with female partners who are or may become pregnant should use a condom during and for at least 4 months after cyclophosphamide treatment.  Cyclophosphamide may cause sterility in males and females (may be irreversible) and amenorrhea in females. When treatment is needed for lupus nephritis, cyclophosphamide should be avoided in women who are pregnant or those who wish to preserve their fertility (Hahn 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chemotherapy, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen (common regimens administered during pregnancy include doxorubicin (or epirubicin), cyclophosphamide, and fluorouracil); chemotherapy should not be administered during the first trimester, after 35 weeks gestation, or within 3 weeks of planned delivery (Amant 2010; Loibl 2006). The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (Peccatori 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046685\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, BUN, urinalysis, urine specific gravity, urine output, serum electrolytes, serum creatinine, monitor for signs/symptoms of hemorrhagic cystitis or other urinary/renal toxicity, pulmonary, cardiac, and/or hepatic toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155414\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155433\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 30 to 50 L (approximates total body water); crosses into CSF (not in high enough concentrations to treat meningeal leukemia) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~20%; some metabolites are bound at &gt;60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to active metabolites acrolein, 4-aldophosphamide, 4-hydroperoxycyclophosphamide, and nor-nitrogen mustard</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: &gt;75% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 3 to 12 hours; Children: 4 hours; Adults: 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: ~1 hour; IV: Metabolites: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (10 to 20% as unchanged drug); feces (4%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155432\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">Liquid solutions for oral administration may be prepared by dissolving cyclophosphamide injection in Aromatic Elixir, N.F. Store refrigerated (in glass container) for up to 14 days.</p>\n    <div class=\"reference\">Cyclophosphamide Prescribing Information, Baxter Healthcare Corporation, Deerfield, Il, May, 2013.<span class=\"pubmed-id\">20103616</span></div>\r\n\n    <p style=\"text-indent:0em;margin-top:2em;\">A 10 mg/mL oral suspension may be prepared by reconstituting one 2 g vial for injection with 100 mL of NaCl 0.9%, providing an initial concentration of 20 mg/mL. Mix this solution in a 1:1 ratio with either Simple Syrup, NF or Ora-Plus to obtain a final concentration of 10 mg/mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 56 days refrigerated.</p>\n    <div class=\"reference\">Kennedy R, Groepper D, Tagen M, et al, &quot;Stability of Cyclophosphamide in Extemporaneous Oral Suspensions,&quot; <i>Ann Pharmacother</i>, 2010, 44(2):295-301.<span class=\"pubmed-id\">20103616</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155437\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cyclophosphamide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $936.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $1,718.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cyclophosphamide Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $685.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $1,371.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $343.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155439\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alkyloxan (KR, SG);</li>\n      <li>Alkyroxan (KR);</li>\n      <li>Cryofaxol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Cycloblastin (AU, NZ);</li>\n      <li>Cycloblastine (LU);</li>\n      <li>Cyclostin (DE);</li>\n      <li>Cyclostin N (DE);</li>\n      <li>Cycram (VN);</li>\n      <li>Cyphos (LK, PH);</li>\n      <li>Cytoxan (CO, HU, ID);</li>\n      <li>Endoksan (UA);</li>\n      <li>Endoxan (AT, AU, BE, BG, CL, CZ, DE, EE, EG, GR, HN, HR, HU, IL, IT, JP, KR, LT, LU, LV, NL, NZ, PK, PL, PT, RO, RU, SG, SI, SK, TR, UY, VN, ZA);</li>\n      <li>Endoxan-Asta (AE, AR, BH, CH, CY, FR, HK, ID, IN, IQ, IR, JO, KW, LB, LY, MY, OM, PH, QA, SA, SY, TH, TW, YE);</li>\n      <li>Endoxana (GB, IE);</li>\n      <li>Endoxon-Asta (AU);</li>\n      <li>Enduxan (BR);</li>\n      <li>Formitex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Genoxal (BR, ES);</li>\n      <li>Hidrofosmin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ledoxan (PH);</li>\n      <li>Ledoxina (MX);</li>\n      <li>Lyophilisate (ID);</li>\n      <li>Neophamid (KR);</li>\n      <li>Neophos (LB);</li>\n      <li>Oncomide (LK);</li>\n      <li>Sendoxan (DK, FI, NO, SE);</li>\n      <li>Syklofosfamid (TR, TW);</li>\n      <li>Uniphos (LK);</li>\n      <li>Xyclomed (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. <i>Eur J Cancer</i>. 2010;46(18):3158-3168.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20932740/pubmed\" target=\"_blank\" id=\"20932740\">20932740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arndt C, Hawkins, D, Anderson JR, et al. Age is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin and Cyclophosphamide. <i>J Clin Oncol</i>. 2004;22(10):1894-1901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15143082/pubmed\" target=\"_blank\" id=\"15143082\">15143082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. <i>J Clin Oncol</i>. 2009;27(31):5182-5188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19770373/pubmed\" target=\"_blank\" id=\"19770373\">19770373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Audino AN, Blatt J, Carcamo B, et.al. High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children. <i>Pediatr Blood Cancer</i>. 2010;54:269-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19827142/pubmed\" target=\"_blank\" id=\"19827142\">19827142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al, &quot;Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,&quot; <i>J Clin Oncol</i>, 2011, 29(31):4189-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertsias GK, Tektonidou M, Amoura Z, et.al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Ann Rheum Dis</i>. 2012;71(11):1771-1782.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22851469/pubmed\" target=\"_blank\" id=\"22851469\">22851469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brodsky RA, Chen AR, Dorr D, et.al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i>. 2010;115:2136-2141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20018919/pubmed\" target=\"_blank\" id=\"20018919\">20018919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. <i>Blood</i>. 1996;87(2): 491-494.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8555470/pubmed\" target=\"_blank\" id=\"8555470\">8555470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24462742 /pubmed\" target=\"_blank\" id=\"24462742 \">24462742 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i>. 2007;109(7):2736-2743.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17138821/pubmed\" target=\"_blank\" id=\"17138821\">17138821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. <i>Blood</i>. 2007;109(10):4582-4585.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17272503/pubmed\" target=\"_blank\" id=\"17272503\">17272503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chantada G, Fandi&ntilde;o A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. <i>Med Pediatr Oncol</i>. 2003;40(3):158-161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12518344/pubmed\" target=\"_blank\" id=\"12518344\">12518344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15611503/pubmed\" target=\"_blank\" id=\"15611503\">15611503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cyclophosphamide Capsules [prescribing information]. Columbus, OH: Roxane; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cyclophosphamide Injection and Tablets [prescribing information]. Deerfield, IL: Baxter; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Groot K, Harper L, Jayne DR, et al, &ldquo;Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial,&rdquo; <i>Ann Intern Med</i>, 2009, 150(10):670-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19451574/pubmed\" target=\"_blank\" id=\"19451574\">19451574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeZern AE, Petri M, Drachman DB, et.al. High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. <i>Medicine</i>. 2011;90:89-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21358440/pubmed\" target=\"_blank\" id=\"21358440\">21358440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 2015;92(1):60-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25542311/pubmed\" target=\"_blank\" id=\"25542311\">25542311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol. </i>2016;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D'Incalci M, Sessa C, Colombo N, et al. Transplacental passage of cyclophosphamide. <i>Cancer Treat Rep</i>. 1982;66(8):1681-1682.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7105061/pubmed\" target=\"_blank\" id=\"7105061\">7105061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo; <i>Pediatr Blood Cancer</i>, 2011, 57(2):191-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durodola JI. Administration of cyclophosphamide during late pregnancy and early lactation: a case report. <i>J Natl Med Assoc</i>. 1979;71(2):165-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/423292/pubmed\" target=\"_blank\" id=\"423292\">423292</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JD, Nguyen DT, Lobins RL, et al, &quot;Cardiotoxicity of Cancer Therapy,&quot; <i>J Clin Oncol</i>, 2005, 23(30):7685-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16234530/pubmed\" target=\"_blank\" id=\"16234530\">16234530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25311218/pubmed\" target=\"_blank\" id=\"25311218\">25311218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gipson DS, Massengill SF, Yao L, et.al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. <i>2009</i>. 124:747-757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19651590/pubmed\" target=\"_blank\" id=\"19651590\">19651590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22940833/pubmed\" target=\"_blank\" id=\"22940833\">22940833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>Br J Haematol</i>. 2014;167(3):394-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25066629/pubmed\" target=\"_blank\" id=\"25066629\">25066629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green DM, Beckwith JB, Breslow NE, et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. <i>J Clin Oncol</i>. 1994;12(10):2126-2131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7931483/pubmed\" target=\"_blank\" id=\"7931483\">7931483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green DM, Cotton CA, Malogolowkin M, et al, &quot;Treatment of Wilms Tumor Relapsing After Initial Treatment With Vincristine and Actinomycin D: A Report From the National Wilms Tumor Study Group,&quot; <i>Pediatr Blood Cancer</i>, 2007, 48(5):493-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16547940/pubmed\" target=\"_blank\" id=\"16547940\">16547940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grier HE, Krailo MD, Tarbell NJ, et al, &ldquo;Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,&rdquo; <i>N Engl J Med</i>, 2003, 348(8):694-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12594313/pubmed\" target=\"_blank\" id=\"12594313\">12594313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. <i>Am J Transplant</i>. 2012;12(11):3069-3075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22883417/pubmed\" target=\"_blank\" id=\"22883417\">22883417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn KM, Johnson PH, Gordon N, et al, &quot;Treatment of Pregnant Breast Cancer Patients and Outcomes of Children Exposed to Chemotherapy <i>In utero</i>,&quot; <i>Cancer</i>, 2006, 107(6):1219-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16894524/pubmed\" target=\"_blank\" id=\"16894524\">16894524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. <i>Blood</i>. 2011;118(23):6043-6049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21967976/pubmed\" target=\"_blank\" id=\"21967976\">21967976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jabs DA, Rosenbaum JT, Foster CS, et.al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. <i>Am J Ophthalmol. </i>2000;130: 492-513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11024423/pubmed\" target=\"_blank\" id=\"11024423\">11024423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaime-Perez JC, Gonzalez-Llano O, Cantu-Rodriguez OG, et.al. Long-term remission and bone marrow findings in children with severe aplastic anemia immunosuppressed with high doses of cyclophosphamide. <i>Journal of Bone Marrow Research</i>. 2013;1(1):1-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al, &quot;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&quot; <i>Ann Oncol</i>, 2010, 21(7):1395-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDIGO. Clinical Practice Guideline for Glomerulonephritis. <i>Kidney International Supplements</i>. June 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDIGO. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. <i>Am J Kidney Dis</i>. 2013;62(3):403-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23871408/pubmed\" target=\"_blank\" id=\"23871408\">23871408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Sposto R, Hutchinson R, et al, &ldquo;BEACOPP Chemotherapy is a Highly Effective Regimen in Children and Adolescents With High-Risk Hodgkin lymphoma: A Report from the Children&rsquo;s Oncology Group,&rdquo; <i>Blood</i>, 2011, 117(9):2596-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21079154/pubmed\" target=\"_blank\" id=\"21079154\">21079154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krmar RT, Kagebrand M, Hansson MEA, et.al. Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis. <i>Clinical Nephrology</i>. 2013;80:388-394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22541686/pubmed\" target=\"_blank\" id=\"22541686\">22541686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. <i>Cancer</i>. 2010;116(12):3054-3060.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20564411/pubmed\" target=\"_blank\" id=\"20564411\">20564411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Kramer K, Modak S, Yataghene K, Cheung NK. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. <i>Eur J Cancer</i>. 2011;47(1):84-89<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20934323/pubmed\" target=\"_blank\" id=\"20934323\">20934323</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. <i>J Clin Oncol</i>. 1996;14(5):1526-1531.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8622067/pubmed\" target=\"_blank\" id=\"8622067\">8622067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman TJ and Onel K, &ldquo;Intermittent Intravenous Cyclophosphamide Arrests Progression of the Renal Chronicity Index in Childhood Systemic Lupus Erythematosus,&rdquo; <i>J Pediatr</i>, 2000, 136(2):243-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10657833/pubmed\" target=\"_blank\" id=\"10657833\">10657833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Locatelli F, N&ouml;llke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. <i>Blood</i>. 2005;105(1):410-419.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15353481/pubmed\" target=\"_blank\" id=\"15353481\">15353481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. <i>Cancer</i>. 2006;106(2):237-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16342247/pubmed\" target=\"_blank\" id=\"16342247\">16342247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. <i>Pediatr Blood Cancer</i>. 2008;50(2):236-241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17539021/pubmed\" target=\"_blank\" id=\"17539021\">17539021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malik SW, Myers JL, DeRemee RA, et al, &quot;Lung Toxicity Associated With Cyclophosphamide Use. Two Distinct Patterns,&quot; <i>Am J Respir Crit Care Med</i>, 1996, 154(6 Pt 1):1851-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8970380/pubmed\" target=\"_blank\" id=\"8970380\">8970380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&aring;rtensson T1, Priftakis P, Casswall T, et al. Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning. <i>Pediatr Transplant</i>. 2013;17(3):285-293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23489519/pubmed\" target=\"_blank\" id=\"23489519\">23489519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. <i>J Clin Oncol</i>. 1998;16(1):210-221.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9440745/pubmed\" target=\"_blank\" id=\"9440745\">9440745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mina R, Scheven E, Ardoin SP, et.al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(3):375-383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22162255/pubmed\" target=\"_blank\" id=\"22162255\">22162255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mok CC, Lau CS, and Wong RW, &quot;Risk Factors for Ovarian Failure in Patients With Systemic Lupus Erythematosus Receiving Cyclophosphamide Therapy,&quot; <i>Arthritis Rheum</i>, 1998, 41(5):831-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9588734/pubmed\" target=\"_blank\" id=\"9588734\">9588734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &quot;Management of Uncommon Chemotherapy-Induced Emergencies,&quot; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. <i>Lancet</i>. 2010;376(9757):2009-2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21131038/pubmed\" target=\"_blank\" id=\"21131038\">21131038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. <i>Blood</i>. 2007;109(7):2773-2780.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17132719/pubmed\" target=\"_blank\" id=\"17132719\">17132719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24 Suppl 6:vi160-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23813932/pubmed\" target=\"_blank\" id=\"23813932\">23813932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phelps SJ, Hak EB, Crill CM, eds. <i>Teddy Bear Book: Pediatric Injectable Drugs</i>. 10th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procytox (cyclophosphamide) [product monograph]. Mississauga, Ontario, Canada: Baxter; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pujari SS, Kempen JH, Newcomb CW, et.al. Cyclophosphamide for ocular inflammatory diseases. <i>Ophthalmology</i>. 2010;117(2):356-365.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. <i>J Clin Oncol</i>. 1994;12(5):899-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8164040/pubmed\" target=\"_blank\" id=\"8164040\">8164040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. <i>Pediatr Blood Cancer</i>. 2014;61(4):636-642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24123865/pubmed\" target=\"_blank\" id=\"24123865\">24123865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia Consensus Conference. <i>Ann Oncol</i>. 2010;21(Suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. <i>J Clin Oncol</i>. 2011;29(4):449-455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21172879/pubmed\" target=\"_blank\" id=\"21172879\">21172879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Michon J, Plantaz D, et al, &ldquo;Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP),&rdquo; <i>Br J Cancer</i>, 1998, 77(12):2310-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9649151 /pubmed\" target=\"_blank\" id=\"9649151 \">9649151 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Plantaz D, Coze C, et al, &quot;Localised and Unresectable Neuroblastoma in Infants: Excellent Outcome With Primary Chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique,&quot; <i>Med Pediatr Oncol</i>, 2001, 36(1):247-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11464897/pubmed\" target=\"_blank\" id=\"11464897\">11464897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19584400/pubmed\" target=\"_blank\" id=\"19584400\">19584400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-M&uuml;nster Group Trial NHL-BFM 90. <i>Blood</i>. 2001;97(12):3699-3706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11389005/pubmed\" target=\"_blank\" id=\"11389005\">11389005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. <i>Autoimmun Rev</i>. 2010;9(10):674-683<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20553975/pubmed\" target=\"_blank\" id=\"20553975\">20553975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. <i>Cancer</i>. 1993;72(10):3120-3130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8221579/pubmed\" target=\"_blank\" id=\"8221579\">8221579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. <i>Pediatrics</i>. 2000;105(6):E78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10835091/pubmed\" target=\"_blank\" id=\"10835091\">10835091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterhouse DO, Pappo AS, Meza JL, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>J Clin Oncol</i>. 2014;32(31):3547-3552.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25267746/pubmed\" target=\"_blank\" id=\"25267746\">25267746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13191 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F155456\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046686\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F25472595\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046677\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F155426\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F155411\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046690\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130947\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F155448\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046689\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F155519\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F155515\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F155434\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F155415\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F155504\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F155420\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F155422\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13494887\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046685\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F155414\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F155433\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F155432\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F155437\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F155439\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13191|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">Cyclophosphamide: Drug information</a></li><li><a href=\"topic.htm?path=cyclophosphamide-patient-drug-information\" class=\"drug drug_patient\">Cyclophosphamide: Patient drug information</a></li></ul></div></div>","javascript":null}